SXTP

60 Degrees Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

2.250

-0.140(-5.860%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

2.400

Open

2.400

VWAP

2.30

Vol

23.00K

Mkt Cap

3.31M

Low

2.2101

Amount

52.84K

EV/EBITDA(TTM)

Total Shares

12.21M

9.78M

EV/OCF(TTM)

P/S(TTM)

2.08

60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Its lead product, ARAKODA (tafenoquine), is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years and older. The Company's pipeline under development covers development programs for COVID-19, fungal, tick-borne, and other viral diseases; new products that contain the Arakoda regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. The ARAKODA regimen of tafenoquine is in Phase II study data in patients with mild-moderate COVID-19 disease. It is also planning a clinical study to assess the utility of ARAKODA as a treatment for human babesiosis. The Company is also developing Celgosivir for the treatment of COVID-19, respiratory syncytial virus (RSV), and dengue.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q2

FY2025Q1

438.00K

+223.75%

-1.380

-68.19%

376.50K

+201.27%

-1.280

-93.77%

301.00K

+158.46%

-1.320

-83.26%

Estimates Revision

The market is revising Downward the revenue expectations for 60 Degrees Pharmaceuticals, Inc. (SXTP) for FY2025, with the revenue forecasts being adjusted by -11.6% over the past three months. During the same period, the stock price has changed by -13.86%.

Revenue Estimates for FY2025

Revise Downward

-11.6%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-13.86%

In Past 3 Month

1 Analyst Rating

51.11% Upside

Wall Street analysts forecast SXTP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SXTP is 3.40 USD with a low forecast of 3.40 USD and a high forecast of 3.40 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

1 Hold

0 Sell

Hold

51.11% Upside

Current: 2.250

Low

3.40

Averages

3.40

High

3.40

51.11% Upside

Current: 2.250

Low

3.40

Averages

3.40

High

3.40

HC Wainwright & Co.

Edward White

Hold

Reiterates

n/a

2025-03-28

Reason

HC Wainwright & Co.

Edward White

Price Target

n/a

2025-03-28

Reiterates

Hold

Reason

HC Wainwright & Co.

Edward White

Hold

Reiterates

n/a

2025-01-10

Reason

HC Wainwright & Co.

Edward White

Price Target

n/a

2025-01-10

Reiterates

Hold

Reason

HC Wainwright & Co.

Edward White

Hold

Reiterates

n/a

2024-12-23

Reason

HC Wainwright & Co.

Edward White

Price Target

n/a

2024-12-23

Reiterates

Hold

Reason

HC Wainwright & Co.

Edward White

Hold

Reiterates

n/a

2024-12-11

Reason

HC Wainwright & Co.

Edward White

Price Target

n/a

2024-12-11

Reiterates

Hold

Reason

HC Wainwright & Co.

Edward White

Hold

Reiterates

n/a

2024-11-15

Reason

HC Wainwright & Co.

Edward White

Price Target

n/a

2024-11-15

Reiterates

Hold

Reason

HC Wainwright & Co.

Edward White

Hold

Reiterates

n/a

2024-09-13

Reason

HC Wainwright & Co.

Edward White

Price Target

n/a

2024-09-13

Reiterates

Hold

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for 60 Degrees Pharmaceuticals Inc (SXTP.O) is -0.45, compared to its 5-year average forward P/E of -0.90. For a more detailed relative valuation and DCF analysis to assess 60 Degrees Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-0.90

Current PE

-0.45

Overvalued PE

-0.02

Undervalued PE

-1.77

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

4.95

Current PS

2.21

Overvalued PS

10.79

Undervalued PS

-0.90

Financials

Annual

Quarterly

FY2024Q4

YoY :

+512.17%

261.44K

Total Revenue

FY2024Q4

YoY :

+9.59%

-2.08M

Operating Profit

FY2024Q4

YoY :

+0.13%

-2.05M

Net Income after Tax

FY2024Q4

YoY :

-89.65%

-2.28

EPS - Diluted

FY2024Q4

YoY :

+1159.55%

-1.64M

Free Cash Flow

FY2024Q4

YoY :

-122.62%

54.84

Gross Profit Margin - %

FY2024Q4

YoY :

-83.64%

-783.71

Net Margin - %

Trading Trends

Insider

Insiders areBuying! The selling amount has increased 1645.8% over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

111.2K

USD

Months

6-9

6.4K

USD

Months

0-12

8.5K

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders areBuying! The selling amount has increased 1645.8% over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

111.2K

USD

Months

6-9

6.4K

USD

Months

0-12

8.5K

USD

Months

SXTP News & Events

Events Timeline

2025-04-22 (ET)

2025-04-22

08:47:10

60 Degrees announces findings from online survey about babesiosis disease

2025-04-08 (ET)

2025-04-08

08:36:21

60 Degrees Pharmaceuticals signs Patient License Agreement with Yale

2025-02-19 (ET)

2025-02-19

21:37:38

60 Degrees Pharmaceuticals announces 1-for-5 reverse stock split

News

1.0

04-10Newsfilter

Geoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21

9.5

04-08Benzinga

Crude Oil Gains 1%; Walgreens Posts Upbeat Earnings

4.5

04-08Benzinga

Dow Jumps Over 1,100 Points; US Small Business Sentiment Falls In March

People Also Watch

FAQ

What is 60 Degrees Pharmaceuticals Inc (SXTP) stock price today?

The current price of SXTP is 2.25 USD — it has decreased -5.86 % in the last trading day.

SXTP

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

SXTP News & Events

Events Timeline

News

People Also Watch

FAQ

What is 60 Degrees Pharmaceuticals Inc (SXTP) stock price today?

What is 60 Degrees Pharmaceuticals Inc (SXTP)'s business?

What is the price predicton of SXTP Stock?

What is 60 Degrees Pharmaceuticals Inc (SXTP)'s revenue for the last quarter?

What is 60 Degrees Pharmaceuticals Inc (SXTP)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for 60 Degrees Pharmaceuticals Inc (SXTP)'s fundamentals?

How many employees does 60 Degrees Pharmaceuticals Inc (SXTP). have?

What is 60 Degrees Pharmaceuticals Inc (SXTP) market cap?